Global Economic Losses from Antimicrobial Resistance Reach $3.5 Trillion in 2021
A new study reveals that antimicrobial resistance led to staggering economic losses worldwide, emphasizing urgent health challenges.
AMR linked to $3.5 trillion in global losses in 2021
South Asia faces the highest economic burden at $101 billion
Need for improved antimicrobial stewardship and diagnostics.
A recent study presented at IDWeek 2026 has revealed that antimicrobial resistance (AMR) was responsible for an estimated $3.5 trillion in global economic losses in 2021. This alarming figure highlights the escalating health and financial repercussions of infections that are increasingly resistant to treatment.
The research indicates that the economic impact of AMR accounted for approximately 2.25% of the global gross domestic product (GDP). Out of this total, $835 billion was directly linked to antimicrobial resistance, representing 0.54% of the global GDP. The study analyzed data from 21 regions, 12 infectious syndromes, and 22 bacterial pathogens to arrive at these conclusions.
Key findings revealed that bloodstream and lower respiratory infections were the primary contributors to the economic losses, together accounting for 73.8% of the total losses attributable to AMR. Bloodstream infections alone were responsible for an estimated $355 billion in economic damage. Six bacterial pathogens were identified as significant contributors, with Klebsiella pneumoniae leading at $130 billion, followed closely by Streptococcus pneumoniae and Acinetobacter baumannii.
Regionally, South Asia experienced the highest absolute economic losses at $101 billion, followed by East Asia at $82 billion and North America at $70 billion. In terms of proportional burden, Western sub-Saharan Africa faced the most severe impact, with losses equivalent to 1.42% of its regional GDP. The data underscores the urgent need for enhanced antimicrobial stewardship, rapid diagnostics, vaccination strategies, and equitable access to effective antibiotics.
Looking ahead, the findings emphasize the importance of addressing antimicrobial resistance through comprehensive public health strategies and international cooperation. Continued research and investment in healthcare infrastructure will be crucial in mitigating the economic and health impacts of AMR in the coming years.
